Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7458312 | 0.97 | KDM4E (0.58) | KDM4ECYP1A2CYP3A4CYP2D6HTR2A | |
| SCHEMBL7464185 | 0.96 | KDM4E (0.57) | KDM4ECYP1A2CYP3A4CYP2D6HTR2A | |
| Fumaric Acid SCHEMBL7464795 | 0.91 | HTR2A (0.50) | KDM4ECYP1A2CYP3A4CYP2D6HTR2A | |
| Fumaric Acid SCHEMBL7464788 | 0.91 | HTR2A (0.50) | KDM4ECYP1A2CYP3A4CYP2D6HTR2A | |
| Hydrochloric Acid SCHEMBL7458703 | 0.87 | CCR5 (0.59) | CCR5KCNH2 | |
| SCHEMBL7464796 | 0.86 | HTR2A (0.48) | KDM4ECYP1A2CYP3A4CYP2D6HTR2A | |
| Hydrochloric Acid SCHEMBL7465744 | 0.86 | CCR5 (0.62) | CCR5 | |
| SCHEMBL7463510 | 0.85 | CCR5 (0.48) | CYP1A2HTR2ACCR5HTR2C | |
| SCHEMBL7469296 | 0.83 | HTR1A (0.47) | HTR2ACCR5HTR2C | |
| Hydrochloric Acid SCHEMBL7468181 | 0.82 | CCR5 (0.50) | CYP2D6HTR2ACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108586-A1 | COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION | INCYTE CORPORATION (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2008030853-A2 | COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION | INCYTE CORPORATION (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-1180513-A1 | CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108586-A1 | COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION | CCR5, HAVCR2, CXCR3 | KDM4E 3999/4885CYP1A2 3242/4885CYP3A4 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.